Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma

被引：0

作者：

Hideki Goto ^{[1
]}

Masashi Sawa ^{[2
]}

Shin-ichiro Fujiwara ^{[3
]}

Masaki Ri ^{[4
]}

Tadao Ishida ^{[5
]}

Masahiro Takeuchi ^{[6
]}

Kenji Ishitsuka ^{[7
]}

Masako Toyosaki ^{[8
]}

Kazutaka Sunami ^{[9
]}

Junichi Tsukada ^{[10
]}

Takashi Sonoki ^{[11
]}

Aiko Shimogomi ^{[12
]}

Yuki Ichihashi ^{[13
]}

Yoshiumi Ouchi ^{[13
]}

Toshihiro Miyamoto ^{[13
]}

Masayuki Hino ^{[14
]}

Yoshinobu Maeda ^{[15
]}

Takanori Teshima ^{[16
]}

机构：

[1] Department of Hematology, Graduate School of Medicine, Hokkaido University Faculty of Medicine, Sapporo

[2] Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo

[3] Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo

[4] Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke

[5] Department of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya

[6] Department of Hematology, Japanese Red Cross Medical Center, Tokyo

[7] Division of Hematology-Oncology, Chiba Cancer Center, Chiba

[8] Department of Hematology and Rheumatology, Kagoshima University, Kagoshima

[9] Department of Hematology and Oncology, School of Medicine, Tokai University, Isehara

[10] Department of Hematology, NHO Okayama Medical Center, Okayama

[11] Department of Hematology, University of Occupational and Environmental Health, Kitakyushu

[12] Department of Hematology/Oncology, Wakayama Medical University, Wakayama

[13] Kyowa Kirin Co., Ltd, Tokyo

[14] Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa

[15] Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka

[16] Department of Hematology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama

来源：

Scientific Reports | / 15卷 / 1期

关键词：

CD34; Lymphoma; Mobilization; Multiple myeloma; Pegfilgrastim; Peripheral blood stem cell;

D O I：

10.1038/s41598-025-98453-7

中图分类号：

学科分类号：

摘要：

This phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or malignant lymphoma (ML). Efficacy and safety, along with CD34-positive cell mobilization outcomes were assessed in patients with MM, who were randomly assigned to pegfilgrastim (n = 30) or daily filgrastim (n = 31), and ML (pegfilgrastim only, n = 13) cohorts. In the MM cohort, CD34-positive cell counts ≥ 2 × 106/kg were achieved in 100% of patients in the pegfilgrastim group and 96.7% in the filgrastim group (difference: 3.3%; 80% confidence interval: −0.9–7.5%), demonstrating the non-inferiority of pegfilgrastim to filgrastim. All patients in the ML cohort achieved ≥ 2 × 106/kg CD34-positive cell counts. The plerixafor administration rates in the MM cohort were 50.0% and 63.3% in the pegfilgrastim and filgrastim groups, respectively, and 91.7% in the ML cohort. There were no major differences in safety measures between the two groups. Although the sample size was small, particularly in the ML cohort, a single dose of pegfilgrastim demonstrated comparable efficacy and safety to daily doses of filgrastim, indicating its potential for clinical use while reducing patient burden. Trial Registration: jRCT2011210029, NCT05007652. © The Author(s) 2025.

引用

共 45 条

[1]

Duong H.K., Et al., Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation, Biol. Blood Marrow Transpl, 20, pp. 1262-1273, (2014)

[2]

Palumbo A., Et al., Autologous transplantation and maintenance therapy in multiple myeloma, N Engl. J. Med, 371, pp. 895-905, (2014)

[3]

Wang J., Et al., Comparison of survival between autologous and allogeneic stem cell transplantation in patients with relapsed or refractory b-cell non-Hodgkin lymphoma: a meta-analysis, Cell. Transpl, 29, (2020)

[4]

Cornelissen J.J., Blaise D., Hematopoietic stem cell transplantation for patients with AML in first complete remission, Blood, 127, pp. 62-70, (2016)

[5]

Kroger N., Et al., Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study), J. Clin. Oncol, 39, pp. 3318-3327, (2021)

[6]

Jillella A.P., Ustun C., What is the optimum number of CD34 + peripheral blood stem cells for an autologous transplant?, Stem Cells Dev, 13, pp. 598-606, (2004)

[7]

Wuchter P., Et al., Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation, Biol. Blood Marrow Transpl, 16, pp. 490-499, (2010)

[8]

Aladag Karakulak E., Et al., CD34 + hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation, Turk. J. Med. Sci, 50, pp. 1851-1856, (2020)

[9]

Curran M.P., Goa K.L., Pegfilgrastim Drugs, 62, pp. 1207-1215, (2002)

[10]

Kroger N., Et al., A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation, Br. J. Haematol, 111, pp. 761-765, (2000)

← 1 2 3 4 5 →